論文
1. Tanaka H, Okada Y, Nakayamada S, Miyazaki Y, Sonehara K, Namba S, Honda S, Shirai Y, Yamamoto K, Kubo S, Ikari K, Harigai M, Sonomoto K, Tanaka Y. Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Ann Rheum Dis 2024;83(2):242-52.
2. Todoroki Y, Satoh M, Kubo S, Kosaka S, Fukuyo S, Nakatsuka K, Saito K, Tanaka S, Nakayamada S, Tanaka Y. Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in Mixed connective tissue disease. Rheumatology (Oxford) 2024;63(4):1068-75.
3. Kubo S, Tanaka Y. Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease. Immunol Med 2024:1-6.
4. Park AY, Leney-Greene M, Lynberg M, Gabrielski JQ, Xu X, Schwarz B, Zheng L, Balasubramaniyam A, Ham H, Chao B, Zhang Y, Matthews HF, Cui J, Yao Y, Kubo S, Chanchu JM, Morawski AR, Cook SA, Jiang P, Ravell JC, Cheng YH, George A, Faruqi A, Pagalilauan AM, Bergerson JRE, Ganesan S, Chauvin SD, Aluri J, Edwards-Hicks J, Bohrnsen E, Tippett C, Omar H, Xu L, Butcher GW, Pascall J, Karakoc-Aydiner E, Kiykim A, Maecker H, Tezcan I, Esenboga S, Heredia RJ, Akata D, Tekin S, Kara A, Kuloglu Z, Unal E, Kendirli T, Dogu F, Karabiber E, Atkinson TP, Cochet C, Filhol O, Bosio CM, Davis MM, Lifton RP, Pearce EL, Daumke O, Aytekin C, Sahin GE, Aksu AU, Uzel G, Koneti Rao V, Sari S, Boztug K, Cagdas D, Haskologlu S, Ikinciogullari A, Schwefel D, Vilarinho S, Baris S, Ozen A, Su HC, Lenardo MJ. GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway. Nat Immunol 2024.
5. Kubo S, Miyazaki Y, Amano K, Matsui K, Kameda H, Inoue Y, Nakayamada S, Ogura T, Kaneko Y, Yamaoka K, Tanaka Y. Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study. RMD Open 2023;9(2).
6. Sonomoto K, Nakayamada S, Fujino Y, Miyata H, Kubo S, Fujita Y, Inoue Y, Matsunaga S, Iwata S, Hanami K, Todoroki Y, Yoshinari-Korekoda H, Kawabe A, Yamaguchi A, Ueno M, Satoh-Kanda Y, Kanda R, Funada M, Ohkubo N, Kusaka K, Kosaka S, Nagayasu A, Fukuyo S, Nawata M, Miyazaki Y, Tokunaga M, Tanaka K, Okada Y, Tanaka Y. Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. Rheumatology (Oxford) 2023.
7. Miyazaki Y, Funada M, Nakayamada S, Sonomoto K, Tanaka H, Hanami K, Fukuyo S, Kubo S, Yamaguchi A, Miyagawa I, Todoroki Y, Ueno M, Tanaka Y. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology (Oxford) 2023.
8. Kubo S, Nakayamada S, Tanaka Y. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 2023;32(4):333-44.
9. Lauper K, Mongin D, Bergstra SA, Choquette D, Codreanu C, Gottenberg JE, Kubo S, Hetland ML, Iannone F, Kristianslund EK, Kvien TK, Lukina G, Mariette X, Nordstrom DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Tanaka Y, Turesson C, Courvoisier DS, Finckh A, Gabay C. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies. Joint Bone Spine 2023;91(2):105671.
10. Kubo S, Miyazaki Y, Todoroki Y, Nagayasu A, Kanda R, Aritomi T, Matsunaga S, Ueno M, Miyagawa I, Sonomoto K, Hanami K, Nakayamada S, Tanaka Y. Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry. Rheumatol Ther 2023;10(6):1705-23.
11. Tokutsu A, Okada Y, Kurozumi A, Tanaka K, Kubo S, Tanaka Y. Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis. J Bone Miner Metab 2023;41(2):212-9.
12. Miyagawa I, Nakayamada S, Ueno M, Miyazaki Y, Ohkubo N, Inoue Y, Kubo S, Tanaka Y. Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Front Med (Lausanne) 2022;9:934937.
13. Ueno M, Miyagawa I, Miyazaki Y, Hanami K, Fukuyo S, Kubo S, Nakayamada S, Tanaka Y. Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. Arthritis Res Ther 2022;24(1):240.
14. Ueno M, Miyagawa I, Aritomi T, Kimura K, Iwata S, Hanami K, Fukuyo S, Kubo S, Miyazaki Y, Nakayamada S, Tanaka Y. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. Arthritis Res Ther 2022;24(1):159.
15. Miyagawa I, Nakayamada S, Ueno M, Miyazaki Y, Iwata S, Kubo S, Sonomoto K, Anan J, Ohkubo N, Inoue Y, Tanaka Y. Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. Arthritis Res Ther 2022;24(1):86.
16. Kubo S, Kanda R, Nawata A, Miyazaki Y, Kawabe A, Hanami K, Nakatsuka K, Saito K, Nakayamada S, Tanaka Y. Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. RMD Open 2022;8(1).
17. Todoroki Y*, Kubo S* (*Equal contribution), Nakano K, Miyazaki Y, Ueno M, Satoh-Kanda Y, Kanda R, Miyagawa I, Hanami K, Nakatsuka K, Saito K, Nakayamada S, Tanaka Y. Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology (Oxford) 2022;61(12):4875-84.
18. Yao Y, Du Jiang P, Chao BN, Cagdas D, Kubo S, Balasubramaniyam A, Zhang Y, Shadur B, NaserEddin A, Folio LR, Schwarz B, Bohrnsen E, Zheng L, Lynberg M, Gottlieb S, Leney-Greene MA, Park AY, Tezcan I, Akdogan A, Gocmen R, Onder S, Rosenberg A, Soilleux EJ, Johnson E, Jackson PK, Demeter J, Chauvin SD, Paul F, Selbach M, Bulut H, Clatworthy MR, Tuong ZK, Zhang H, Stewart BJ, Bosio CM, Stepensky P, Clare S, Ganesan S, Pascall JC, Daumke O, Butcher GW, McMichael AJ, Simon AK, Lenardo MJ. GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans. J Exp Med 2022;219(6).
19. Kubo S, Kataria R, Yao Y, Gabrielski JQ, Zheng L, Markowitz TE, Chan W, Song J, Boddapati AK, Saeki K, Haupl B, Park AY, Cheng YH, Cui J, Oellerich T, Lenardo MJ. Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells. Proc Natl Acad Sci U S A 2022;119(33):e2208522119.
20. Torimoto K, Okada Y, Nakayamada S, Kubo S, Kurozumi A, Narisawa M, Tanaka Y. Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease. Sci Rep 2022;12(1):16880.
21. Kubo S, Fritz JM, Raquer-McKay HM, Kataria R, Vujkovic-Cvijin I, Al-Shaibi A, Yao Y, Zheng L, Zou J, Waldman AD, Jing X, Farley TK, Park AY, Oler AJ, Charles AK, Makhlouf M, AbouMoussa EH, Hasnah R, Saraiva LR, Ganesan S, Al-Subaiey AA, Matthews H, Flano E, Lee HH, Freeman AF, Sefer AP, Sayar E, Cakir E, Karakoc-Aydiner E, Baris S, Belkaid Y, Ozen A, Lo B, Lenardo MJ. Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease. Nat Immunol 2022;23(1):75-85.
22. Yao Y, Kim G, Shafer S, Chen Z, Kubo S, Ji Y, Luo J, Yang W, Perner SP, Kanellopoulou C, Park AY, Jiang P, Li J, Baris S, Aydiner EK, Ertem D, Mulder DJ, Warner N, Griffiths AM, Topf-Olivestone C, Kori M, Werner L, Ouahed J, Field M, Liu C, Schwarz B, Bosio CM, Ganesan S, Song J, Urlaub H, Oellerich T, Malaker SA, Zheng L, Bertozzi CR, Zhang Y, Matthews H, Montgomery W, Shih HY, Jiang J, Jones M, Baras A, Shuldiner A, Gonzaga-Jauregui C, Snapper SB, Muise AM, Shouval DS, Ozen A, Pan KT, Wu C, Lenardo MJ. Mucus sialylation determines intestinal host-commensal homeostasis. Cell 2022;185(7):1172-88 e28.
23. Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Iwata S, Hanami K, Fukuyo S, Miyagawa I, Yamaguchi A, Kawabe A, Saito K, Tanaka Y. Serum TNFalpha levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. Arthritis Res Ther 2021;23(1):154.
24. Ueno M, Miyagawa I, Nakano K, Iwata S, Hanami K, Fukuyo S, Kubo S, Miyazaki Y, Kawabe A, Yoshinari H, Nakayamada S, Tanaka Y. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther 2021;23(1):86.
25. Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Inoue Y, Fujino Y, Tanaka Y. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis 2021;80(9):1130-6.
26. Inoue Y, Nakayamada S, Kubo S, Yamagata K, Sonomoto K, Iwata S, Miyazaki Y, Tanaka Y. T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease. Rheumatology (Oxford) 2022;61(9):3854-63.
27. Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, Gottenberg JE, Bergstra SA, Suarez MP, Codreanu C, Kvien TK, Santos MJ, Pavelka K, Hetland ML, Askling J, Turesson C, Kubo S, Tanaka Y, Iannone F, Choquette D, Nordstrom DC, Rotar Z, Lukina G, Gabay C, Van Vollenhoven R, Finckh A. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford) 2021;60(2):820-8.
28. Nakano K, Saito K, Nawata A, Hanami K, Kubo S, Miyagawa I, Fujino Y, Nakayamada S, Tanaka Y. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. Mod Rheumatol 2021;31(1):94-100.
29. Narisawa M, Kubo S, Okada Y, Yamagata K, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y. Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. Bone 2021;142:115616.
30. Kawabe A, Nakano K, Kubo S, Asakawa T, Tanaka Y. Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Res Ther 2020;22(1):136.
31. Miyazaki Y, Nakayamada S, Kubo S, Ishikawa Y, Yoshikawa M, Sakata K, Iwata S, Miyagawa I, Nakano K, Tanaka Y. Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Res Ther 2020;22(1):141.
32. Kubo S, Siebuhr AS, Bay-Jensen AC, Juhl P, Karsdal MA, Satoh Y, Todoroki Y, Nakano K, Nakayamada S, Tanaka Y. Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. Int J Rheum Dis 2020;23(4):532-9.
33. Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Inoue Y, Ueno M, Ohkubo N, Fujita Y, Tanaka Y. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. Int J Rheum Dis 2020;23(4):549-58.
34. Kitanaga Y, Imamura E, Nakahara Y, Fukahori H, Fujii Y, Kubo S, Nakayamada S, Tanaka Y. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology (Oxford) 2020;59(8):1957-68.
35. Lee S, Nakayamada S, Kubo S, Yamagata K, Yoshinari H, Tanaka Y. Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. Rheumatology (Oxford) 2020;59(10):3058-69.
36. Kanda R, Kubo S, Nakano K, Kawabe A, Nawata A, Hanami K, Nakayamada S, Tanaka Y. A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease. Mod Rheumatol Case Rep 2020;4(2):278-82.
37. Kusaka K, Nakano K, Iwata S, Kubo S, Nishida T, Tanaka Y. Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. Mod Rheumatol Case Rep 2020;4(2):253-61.
38. Miyagawa I*, Kubo S* (*Equal contribution), Tanaka Y. A wide perspective of targeted therapies for precision medicine in autoimmune diseases. Expert Review of Precision Medicine and Drug Development 2020;5(6):447-53.
39. Yamaguchi A, Hirata S, Kubo S, Fukuyo S, Hanami K, Nakano K, Nakayamada S, Saito K, Tanaka Y. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. Mod Rheumatol 2020;30(5):799-806.
40. Ueno M, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Tanaka Y. An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. Intern Med 2019;58(7):1023-7.
41. Miyagawa I, Nakano K, Iwata S, Nakayamada S, Saito K, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Tanaka Y. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease. Arthritis Res Ther 2019;21(1):151.
42. Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Inoue Y, Ueno M, Tanaka Y. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. Int J Rheum Dis 2019;22(3):434-42.
43. Kubo S, Nakayamada S, Miyazaki Y, Yoshikawa M, Yoshinari H, Satoh Y, Todoroki Y, Nakano K, Satoh M, Smith V, Cutolo M, Tanaka Y. Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. Rheumatology (Oxford) 2019;58(12):2273-83.
44. Kubo S, Tanaka Y. Scleroderma in an ice-cream shop worker. Rheumatology (Oxford) 2019;58(6):1120-1.
45. Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh M, Nawata A, Satoh Y, Miyagawa I, Saito K, Smith V, Cutolo M, Tanaka Y. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology (Oxford) 2019;58(1):120-30.
46. Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, Yoshikawa M, Yoshinari H, Tanaka Y. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford) 2019;58(2):336-44.
47. Kubo S, Nakayamada S, Tanaka Y. Immunophenotype involved in IgG4-related disease. Mod Rheumatol 2019;29(2):226-30.
48. Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Rev Clin Immunol 2019;15(7):693-700.
49. Tanaka Y, Kubo S, Miyagawa I, Iwata S, Nakayamada S. Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases. Semin Arthritis Rheum 2019;48(6):1146-50.
50. Yoshikawa M, Nakayamada S, Kubo S, Nawata A, Kitanaga Y, Iwata S, Sakata K, Ma X, Wang SP, Nakano K, Saito K, Tanaka Y. Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. Clin Immunol 2019;200:1-9.
51. Tanaka K, Yamagata K, Kubo S, Nakayamada S, Sakata K, Matsui T, Yamagishi SI, Okada Y, Tanaka Y. Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. Bone 2019;128:115034.
52. Smith V, Vanhaecke A, Herrick AL, Distler O, Guerra MG, Denton CP, Deschepper E, Foeldvari I, Gutierrez M, Hachulla E, Ingegnoli F, Kubo S, Muller-Ladner U, Riccieri V, Sulli A, van Laar JM, Vonk MC, Walker UA, Cutolo M, Diseases ESGoMiR. Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". Autoimmun Rev 2019;18(11):102394.
53. Miyazaki Y, Nakayamada S, Kubo S, Nakano K, Iwata S, Miyagawa I, Ma X, Trimova G, Sakata K, Tanaka Y. Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. Frontiers in immunology 2018;9:2901.
54. Sakata K, Nakayamada S, Miyazaki Y, Kubo S, Ishii A, Nakano K, Tanaka Y. Up-Regulation of TLR7-Mediated IFN-alpha Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Frontiers in immunology 2018;9:1957.
55. Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S, Ishii A, Yamagata K, Nakano K, Tanaka Y. Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Frontiers in immunology 2018;9:1510.
56. Noguchi S, Hanami K, Miyata H, Torii R, Shimabukuro I, Kubo S, Obata H, Yoshii C, Yatera K. Pleurisy Caused by Mycobacterium abscessus in a Young Patient with Dermatomyositis: A Case Report and Brief Review of the Literature. Intern Med 2018;57(7):997-1002.
57. Nagayasu A, Kubo S, Nakano K, Nakayamada S, Iwata S, Miyagawa I, Fukuyo S, Saito K, Tanaka Y. IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. Intern Med 2018;57(15):2251-7.
58. Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus 2018;27(7):1202-6.
59. Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 2018;27(5):802-11.
60. Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y, Yoshikawa M, Kitanaga Y, Zhang M, Tanaka Y. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis 2018;77(9):1354-61.
61. Kubo S, Nakayamada S, Zhao J, Yoshikawa M, Miyazaki Y, Nawata A, Hirata S, Nakano K, Saito K, Tanaka Y. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease. Rheumatology (Oxford) 2018;57(3):514-24.
62. Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Yunoue N, Iwata S, Miyagawa I, Hirata S, Nakano K, Saito K, Tanaka Y. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology (Oxford) 2018;57(1):164-74.
63. Kubo S, Smith V, Cutolo M, Tanaka Y. The role of nailfold videocapillaroscopy in patients with systemic sclerosis. Immunol Med 2018;41(3):113-9.
64. Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata S, Hanami K, Saito K, Tanaka Y. Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. Clin Immunol 2018;191:67-74.
65. Tanaka Y, Kubo S, Iwata S, Yoshikawa M, Nakayamada S. B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. Clin Immunol 2018;186:21-5.
66. Gudmann NS, Hirata S, Karsdal MA, Kubo S, Bay-Jensen AC, Tanaka Y. Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. Clinical and experimental rheumatology 2018;36(3):462-70.
67. Kubo S, Yamaoka K, Amano K, Nagano S, Tohma S, Suematsu E, Nagasawa H, Iwata K, Tanaka Y. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology (Oxford) 2017;56(8):1293-301.
68. Torimoto K, Okada Y, Nakayamada S, Kubo S, Tanaka Y. Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. Thyroid 2017;27(10):1335-6.
69. Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K, Hanami K, Iwata S, Miyagawa I, Saito K, Tanaka Y. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. Arthritis Rheumatol 2017;69(10):2029-37.
70. Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y. Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. Clinical and experimental rheumatology 2017;35(4):562-70.
71. Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux NA, Tanaka Y. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Mod Rheumatol 2016;26(6):850-6.
72. Zhao J, Kubo S, Nakayamada S, Shimajiri S, Zhang X, Yamaoka K, Tanaka Y. Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjogren's syndrome. Mod Rheumatol 2016;26(5):716-24.
73. Kurozumi A, Okada Y, Arao T, Miyazaki Y, Yoshikawa M, Torimoto K, Kubo S, Nakayamada S, Tanaka Y. Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report. Endocrinol Diabetes Metab Case Rep 2016;2016:160020.
74. Kubo S, Tanaka Y. Usefulness of nailfold videocapillaroscopy for systemic sclerosis. Inflamm Regen 2016;36:5.
75. Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami K, Saito K, Tanaka Y. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis 2016;75(7):1321-7.
76. Nakayamada S, Kubo S, Iwata S, Tanaka Y. Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2016;17(16):2215-25.
77. Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2016;12(9):911-9.
78. Nakayamada S, Kubo S, Iwata S, Tanaka Y. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs 2016;30(5):407-19.
79. Kubo S, Nakano K, Nakayamada S, Hirata S, Fukuyo S, Sawamukai N, Saito K, Tanaka Y. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Clinical and experimental rheumatology 2016;34(5):834-41.
80. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74(2):389-95.
81. Wang SP, Iwata S, Nakayamada S, Niiro H, Jabbarzadeh-Tabrizi S, Kondo M, Kubo S, Yoshikawa M, Tanaka Y. Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. Rheumatology (Oxford) 2015;54(8):1488-97.
82. Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang SP, Yoshikawa M, Saito K, Tanaka Y. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol 2015;67(1):63-73.
83. Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, Takeuchi T. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia((R)) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol 2014;24(5):754-62.
84. Kubo S, Saito K, Hirata S, Fukuyo S, Yamaoka K, Sawamukai N, Nawata M, Iwata S, Mizuno Y, Tanaka Y. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. Mod Rheumatol 2014;24(1):42-51.
85. Kubo S, Yamaoka K, Maeshima K, Tanaka Y. The possible mode of action of Tofacitinib, a JAK inhibitor. Inflammation and Regeneration 2014;34(3):129-33.
86. Katsuyama T, Saito K, Kubo S, Nawata M, Tanaka Y. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther 2014;16(1):R43.
87. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 2014;73(12):2192-8.
88. Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology (Oxford) 2014;53(5):914-8.
89. Kubo S, Yamaoka K, Tanaka Y. Role of JAKs in myeloid cells and autoimmune diseases. Inflammation and Regeneration 2013;33(3):131-5.
90. Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther 2013;15(5):R135.
91. Hanami K, Nakano K, Saito K, Okada Y, Yamaoka K, Kubo S, Kondo M, Tanaka Y. Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. Bone 2013;56(1):1-8.
92. Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, Sonomoto K, Saito K, Tanaka Y. Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol 2013;23(6):1151-7.
93. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Saito K, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, Yamanaka H. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol 2012;22(3):327-38.
94. Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012;64(6):1790-8.
95. Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol 2011;38(4):633-41.
96. Yamaoka K, Kubo S, Sonomoto K, Maeshima K, Tanaka Y. JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug. Inflammation and Regeneration 2011;31(4):349-53.
97. Kubo S, Iwata S, Saito K, Tanaka Y. Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine 2011;78(5):535-6.
98. Kubo S, Yamaoka K, Saito K, Tanaka Y. Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis. Joint Bone Spine 2011;78(1):99-100.
1. Sonomoto K, Nakayamada S, Fujino Y, Miyata H, Kubo S, Fujita Y, Inoue Y, Matsunaga S, Iwata S, Hanami K, Todoroki Y, Yoshinari-Korekoda H, Kawabe A, Yamaguchi A, Ueno M, Satoh-Kanda Y, Kanda R, Funada M, Ohkubo N, Kusaka K, Kosaka S, Nagayasu A, Fukuyo S, Nawata M, Miyazaki Y, Tokunaga M, Tanaka K, Okada Y, Tanaka Y. Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. Rheumatology (Oxford) 2023.
2. Miyazaki Y, Funada M, Nakayamada S, Sonomoto K, Tanaka H, Hanami K, Fukuyo S, Kubo S, Yamaguchi A, Miyagawa I, Todoroki Y, Ueno M, Tanaka Y. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology (Oxford) 2023.
3. Todoroki Y, Satoh M, Kubo S, Kosaka S, Fukuyo S, Nakatsuka K, Saito K, Tanaka S, Nakayamada S, Tanaka Y. Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in Mixed connective tissue disease. Rheumatology (Oxford) 2023.
4. Kubo S, Miyazaki Y, Todoroki Y, Nagayasu A, Kanda R, Aritomi T, Matsunaga S, Ueno M, Miyagawa I, Sonomoto K, Hanami K, Nakayamada S, Tanaka Y. Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry. Rheumatol Ther 2023;10(6):1705-23.
5. Shan Y, Nakayamada S, Nawata A, Yamagata K, Sonomoto K, Tanaka H, Satoh-Kanda, Y.Nguyen M.P, Todoroki Y, Nagayasu A, Ueno M, Kanda R, Fujita Y, Zhang T, Hao H, Zhou J, Ma X, Anan J, Nguyen A.P, Tanaka Y. TGF-beta3 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus. Rheumatology.2022.
6. Todoroki Y, Kubo S, Nakano K, Miyazaki Y, Ueno M, Satoh Y, Kanda R, Hanami K, Nakatsuka K, Saito K, Nakayamada S and Tanaka Y. Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology. 61(12):4875-84, 2022.
7. Sumikawa MH, Iwata S, Zhang M, Miyata H, Ueno M, Todoroki Y, Nagayasu A, Kanda R,Sonomoto K, Tomrimoto K, Lee S, Nakayamada S, Yamamoto K, Okada Y and Tanaka Y. An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology. 61(7):3049-59,2022.
8. Zhang M, Iwata S, Sonomoto K, Ueno M, Fujita Y, Anan J, Miyazaki Y, Ohkubo N, Sumikawa M.H, Todoroki Y, Miyata H, Nagayasu A, Kanda R, Trimova G, Lee S, Nakayamada S, Sakata K and Tanaka Y.mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. Rheumatology. 61(7):3010-22,2022.
9. Muro Y, Yamano Y, Yoshida K, Oto Y, Nakajima K, Mitsuma T, Kikuchi S, Matsumae A, Ogawa-Momohara M, Takeichi T, Kondoh Y, Katayama M, Todoroki Y, Tanaka Y, Satoh M. and Akiyama M. Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. J Autoimmun.122:102680,2021.
10. Kubo S, Siebuhr AS, Bay-Jensen AC, Juhl P, Karsdal MA, Satoh Y, Todoroki Y, Nakano Y, Nakayamada S and Tanaka Y. Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. Int J Rheum Dis. 23(4):532-9,2020.
11. Iwata S, Zhang M, Hao H, Trimova G, Hajime M, Miyazaki Y, Ohkubo N, Todoroki Y, Miyata H, Ueno M, Nagayasu A, Nakayamada S, Sakata K and Tanaka Y. Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN-gamma Overproduction in T Helper 1 Cells. Front Immunol.11:593103,2020.
12. Zhang M, Iwata S, Hajime M, Ohkubo N, Todoroki Y, Miyata H, Ueno M, Hao H, Zhang T, Nakayamada S, Yamagata K and Yoshiya Tanaka. Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase enhancer of zeste homolog 2. Arthritis Rheumatol.72(7):1143-53,2020.
13. Kubo S, Nakayamada S, Miyazaki Y, Yoshikawa M, Yoshinari H, Satoh Y, Todoroki Y, Nakano K, Satoh M, Smith V, Cutolo M and Tanaka Y. Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. Rheumatology. 58(12):2273-83,2019.
14. Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh Y, Nawata A, Saito K, Satoh M, Smith V, Cutolo M and Tanaka Y. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology.58(1):120-30,2019.
15. Ishikawa Y, Iwata S, Hanami K, Nawata A, Zhang M, Kaoru Y, Shintaro H, Kei S, Todoroki Y, Nakano K, Nakayamada S, Satoh M and Tanaka Y. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther. 20(1):240,2018.
16. Ishikawa Y, Miyagawa I, Nakano K, Satoh Y, Todoroki Y, Kubo S, Nawata A, Nakayamada S, Saito K and Tanaka Y. The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. Modern Rheumatology Case Reports. 1(2):108-112,2017.